Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New appointment at Affimed Therapeutics

This article was originally published in Scrip

Executive Summary

Affimed Therapeutics (Germany) has appointed Dr Christian Hucke to take over responsibility for planning and implementation of the company’s clinical development programmes. He joins from Grünenthal, where he had the overall responsibility for a worldwide Phase III study in pain therapy of cancer patients, as well as a proof-of-concept Phase II study against diabetic polyneuropathy. Before that, Dr Hucke worked in clinical drug development at Paion Deutschland and the ClinPharmCologne TROPON. Affimed is a therapeutic antibody company developing therapeutics as treatments for life threatening diseases with high unmet medical need.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts